Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial

Alderson, D, Cunningham, D, Nankivell, M et al. (14 more authors) (2017) Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial. Lancet Oncology, 18 (9). pp. 1249-1260. ISSN 1470-2045

Abstract

Metadata

Authors/Creators:
  • Alderson, D
  • Cunningham, D
  • Nankivell, M
  • Blazeby, JM
  • Griffin, SM
  • Crellin, A
  • Grabsch, HI ORCID logo https://orcid.org/0000-0001-9520-6228
  • Langer, R
  • Pritchard, S
  • Okines, A
  • Krysztopik, R
  • Coxon, F
  • Thompson, J
  • Falk, S
  • Robb, C
  • Stenning, S
  • Langley, RE
Copyright, Publisher and Additional Information: © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Dates:
  • Accepted: 25 May 2017
  • Published (online): 4 August 2017
  • Published: September 2017
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Cancer and Pathology (LICAP) > Pathology & Tumour Biology (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 25 Jul 2017 09:12
Last Modified: 04 Sep 2017 15:31
Status: Published
Publisher: Elsevier
Identification Number: https://doi.org/10.1016/S1470-2045(17)30447-3

Share / Export

Statistics